United States Biosimilars Market to Reach USD 171.79 billion by 2033, Driven by Cost Containment and Biologic Patent Expirations | DataM Intelligence

The global Biosimilars Market reached USD 22.58 billion in 2024 and is projected to reach USD 171.79 billion by 2033, growing at a CAGR of 25.5% during the forecast period 2025-2033, according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Pfizer received FDA approval for its high-concentration biosimilar of adalimumab, offering improved patient convenience.
✅ In October 2025, the Centres for Medicare & Medicaid Services implemented new reimbursement policies favouring biosimilars in hospital settings.
✅ In October 2025, A major US health system achieved 40% cost savings by switching 15 biologic therapies to biosimilar alternatives.

Japan: Recent Industry Developments

✅ In October 2025, Fujifilm Kyowa Kirin Biologics launched a novel biosimilar for rheumatoid arthritis with enhanced stability.
✅ In October 2025, Japan's Ministry of Health established accelerated approval pathways for biosimilars targeting rare diseases.
✅ In October 2025, Mitsubishi Tanabe Pharma introduced a biosimilar manufacturing platform, reducing production costs by 30%.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/biosimilars-market?jd

Market Trends & Drivers

The Biosimilars Market is experiencing robust growth driven by increasing healthcare cost pressures, patent expirations of major biologics, and growing acceptance among physicians and patients. Key trends include the development of high-concentration formulations, expansion into complex molecules, and increasing regulatory clarity across global markets. The rising prevalence of chronic diseases, government initiatives promoting biosimilar adoption, and demonstrated clinical equivalence to reference products are significantly accelerating market expansion.

Competitive Landscape

The market features intense competition among pharmaceutical companies, biotechnology firms, and specialized biosimilar developers.

Pfizer Inc. leads with comprehensive biosimilar portfolios including oncology and immunology products.
Novartis AG (Sandoz) pioneers biosimilar development with extensive experience and global market presence.
Amgen Inc. combines innovative biologic research with strategic biosimilar development.
Biocon Ltd. partners with global pharmaceutical companies to develop and commercialize biosimilars worldwide.
Celltrion Inc. specializes in monoclonal antibody biosimilars with advanced manufacturing capabilities.
Samsung Bioepis Co., Ltd. develops high-quality biosimilars through strategic partnerships and internal research.
Mylan N.V. (Viatris) offers diverse biosimilar portfolios with focus on accessibility and affordability.
Teva Pharmaceutical Industries Ltd. expands into biosimilars as part of its specialty medicine strategy.
Coherus BioSciences, Inc. focuses on oncology and immunology biosimilars for the US market.
Fresenius Kabi AG develops biosimilars with emphasis on hospital and clinical applications.

Segmentation

By Product Type (Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Granulocyte Colony Stimulating Factor, Follitropin, Interferons, Others)
By Application (Oncology, Chronic Diseases, Autoimmune Diseases, Infectious Diseases, Growth Hormone Deficiency, Haematology, Others)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biosimilars-market?jd

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a market research and consulting firm that bridges the gap between data and decisive action. We specialize in translating top market trends and in-depth analysis into swift, smart solutions for your business.
With a repository of 6,300+ reports across 40+ industries, we provide the robust intelligence that over 200 companies in 50+ countries rely on to power their growth.

This release was published on openPR.